{"id":71392,"date":"2026-05-20T08:54:38","date_gmt":"2026-05-20T08:54:38","guid":{"rendered":"https:\/\/medsbase.com\/ll-37\/"},"modified":"2026-10-15T10:33:57","modified_gmt":"2026-10-15T10:33:57","slug":"ll-37","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-br\/product\/ll-37\/","title":{"rendered":"LL-37 (Pept\u00eddeo Antimicrobiano Catelicidina)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 LL-37?<\/h3>\n<p style=\"margin: 0;\"><strong>LL-37<\/strong> (also called Cathelicidin Antimicrobial Peptide, CAP-18, or FALL-39) is a 37-amino-acid amphipathic \u03b1-helical host-defense peptide \u2014 the only human cathelicidin. It is released by proteinase-3 cleavage from the inactive proform (hCAP-18) and combines direct broad-spectrum antimicrobial activity (against bacteria, fungi, enveloped viruses, and biofilms) with potent immunomodulatory effects: LPS neutralisation, chemotaxis of neutrophils\/monocytes\/T-cells, anti-biofilm action, and pro-angiogenic wound-healing signalling. LL-37 is studied across antimicrobial-resistance studies, wound-healing, atherosclerosis, psoriasis pathogenesis, and oncology. Supplied in 5 mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que voc\u00ea obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-br\/reviews\/\">\ud83d\udce6 Cada pedido \u00e9 coberto pela nossa<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Todo pedido \u00e9 coberto pelo nosso <a href=\"https:\/\/medsbase.com\/pt-br\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Reenvio Garantido<\/strong><\/a> \u2014 se sua encomenda n\u00e3o chegar em 20 dias \u00fateis, n\u00f3s a reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">154947-66-7 (base livre LL-37)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tipo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">pept\u00eddeo de defesa do hospedeiro antimicrobiano cati\u00f4nico anfip\u00e1tico \u03b1-h\u00e9lico de 37 amino\u00e1cidos; a \u00fanica catelicidina humana (produto do gene CAMP); pept\u00eddeo C-terminal ativo liberado por clivagem da proteinase-3 da forma pr\u00f3-inativa hCAP-18; tamb\u00e9m chamado de CAP-18 (Pept\u00eddeo Antimicrobiano Catelicidina C-terminal da forma pr\u00f3 de 18 kDa) e FALL-39 (quando inclui o res\u00edduo F N-terminal do sequenciamento anterior)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>205<\/sub>H<sub>340<\/sub>N<sub>60<\/sub>O<sub>53<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~4.493,3 Da<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequ\u00eancia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">H-Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser-OH (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) \u2014 pept\u00eddeo cati\u00f4nico linear de 37 res\u00edduos; carga l\u00edquida +6 em pH neutro; dobra-se em uma \u03b1-h\u00e9lice anfip\u00e1tica em ambientes lip\u00eddicos\/de membrana. Termina\u00e7\u00f5es N e C livres; sem ponte dissulfeto, sem acila\u00e7\u00e3o, sem PEGila\u00e7\u00e3o.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">P\u00f3 liofilizado (branco a branco amarelado)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA sob solicita\u00e7\u00e3o)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (geladeira) para estoque de trabalho de curto prazo; \u221220 \u00b0C para armazenamento de longo prazo de frascos n\u00e3o abertos. Reconstitu\u00eddo: 2\u20138 \u00b0C, usar em ~14\u201328 dias. Proteger da luz. Evitar ciclos repetidos de congelamento-descongelamento. AMPs cati\u00f4nicos podem adsorver a superf\u00edcies pl\u00e1sticas \u2014 tubos de baixa liga\u00e7\u00e3o (silicone ou Protein LoBind) s\u00e3o recomendados para armazenamento de estoque e dilui\u00e7\u00e3o.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Altamente sol\u00favel em \u00e1gua bacteriost\u00e1tica, \u00e1gua est\u00e9ril ou \u00e1cido ac\u00e9tico dilu\u00eddo (0,01\u20130,1%). Reconstituir em pH \u00e1cido a neutro; evitar tamp\u00f5es com alto teor de sal ou fortemente b\u00e1sicos para solu\u00e7\u00f5es estoque. A \u03b1-h\u00e9lice anfip\u00e1tica pode agregar em alta concentra\u00e7\u00e3o \u2014 preparar dilui\u00e7\u00f5es de trabalho imediatamente antes do uso.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O Que \u00c9 LL-37?<\/h2>\n<p><strong>LL-37<\/strong> \u00e9 o pept\u00eddeo ativo C-terminal de 37 amino\u00e1cidos liberado pela clivagem proteol\u00edtica do pept\u00eddeo antimicrobiano catelicidina humana hCAP-18 \u2014 o \u00fanico produto do gene catelicidina em humanos, codificado pelo <em>CAMP<\/em> gene on chromosome 3. The peptide takes its name from its first two residues (Leu-Leu) and its length (37 residues). It belongs to the cathelicidin family of innate-immunity host-defense peptides found across most vertebrate lineages and represents the central effector molecule in the human cathelicidin arm of innate immunity, alongside the defensin family. Inactive hCAP-18 proform is produced in neutrophil granules, in epithelial surfaces (skin keratinocytes, respiratory and gut epithelium), and in lower amounts by macrophages, NK cells, mast cells, B-cells, and \u03b3\u03b4 T-cells. Activation occurs by proteinase-3 cleavage (in neutrophils) or by kallikrein-5\/kallikrein-7 (in skin), liberating the bioactive 37-mer that adopts a strongly amphipathic \u03b1-helical conformation in membrane-mimetic environments. The peptide carries a +6 net positive charge at neutral pH, with cationic lysine and arginine residues concentrated on one face of the helix and hydrophobic leucine, phenylalanine, isoleucine, and valine residues on the opposing face \u2014 the canonical &#8220;amphipathic \u03b1-helix&#8221; architecture that enables selective interaction with negatively-charged microbial membranes. LL-37 combines two distinct host-defense modalities in a single peptide. Its <strong>atividade antimicrobiana direta<\/strong> abrange bact\u00e9rias Gram-positivas (incluindo resistente \u00e0 meticilina <em>S. aureus<\/em>, MRSA), bact\u00e9rias Gram-negativas (incluindo <em>E. coli<\/em>, <em>K. pneumoniae<\/em>, <em>P. aeruginosa<\/em>), v\u00edrus envelopados (HSV-1, influenza, RSV), fungos (<em>Candida<\/em>) e biofilmes microbianos. Sua <strong>atividade imunomoduladora<\/strong> inclui liga\u00e7\u00e3o e neutraliza\u00e7\u00e3o de lipopolissacar\u00eddeo bacteriano (LPS) e \u00e1cido lipoteicoico, quimiotaxia de neutr\u00f3filos\/mon\u00f3citos\/c\u00e9lulas T\/mast\u00f3citos via receptor de pept\u00eddeo formil semelhante-1 (FPRL1\/FPR2), modula\u00e7\u00e3o da sinaliza\u00e7\u00e3o TLR, supress\u00e3o de tempestades de citocinas induzidas por LPS, indu\u00e7\u00e3o de angiog\u00eanese atrav\u00e9s da sinaliza\u00e7\u00e3o FPRL1 em c\u00e9lulas endoteliais e est\u00edmulo \u00e0 migra\u00e7\u00e3o de queratin\u00f3citos na repara\u00e7\u00e3o de feridas. A desregula\u00e7\u00e3o da LL-37 est\u00e1 implicada na patog\u00eanese da psor\u00edase (onde o excesso de LL-37 forma complexos com DNA pr\u00f3prio para ativar c\u00e9lulas dendr\u00edticas plasmacitoides), aterosclerose e certos tipos de c\u00e2ncer. A LL-37 \u00e9 <strong>n\u00e3o aprovado<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Disrup\u00e7\u00e3o de Membrana + Imunomodula\u00e7\u00e3o<\/h2>\n<p>LL-37 acts through three principal mechanisms documented in published studies:<\/p>\n<ul>\n<li><strong>Disrup\u00e7\u00e3o seletiva de membranas microbianas via inser\u00e7\u00e3o de \u03b1-h\u00e9lice anfip\u00e1tica<\/strong> \u2014 Em solu\u00e7\u00e3o aquosa em massa, a LL-37 \u00e9 em grande parte n\u00e3o estruturada, mas, em contato com uma membrana microbiana carregada negativamente (rica em fosfatidilglicerol, cardiolipina, \u00e1cido lipoteicoico ou LPS), ela se dobra rapidamente em uma \u03b1-h\u00e9lice anfip\u00e1tica. A face cati\u00f4nica interage com a superf\u00edcie ani\u00f4nica da membrana; a face hidrof\u00f3bica se insere na bicamada lip\u00eddica. Em raz\u00f5es pept\u00eddeo-lip\u00eddeo limiares, isso leva \u00e0 forma\u00e7\u00e3o de poros toroidais ou desintegra\u00e7\u00e3o da membrana no estilo \u201ctapete\u201d, despolarizando a c\u00e9lula microbiana e perturbando gradientes transmembrana essenciais. As membranas das c\u00e9lulas mam\u00edferas s\u00e3o protegidas por sua folha externa zwitteri\u00f4nica (fosfatidilcolina, esfingomielina) e pela presen\u00e7a de colesterol \u2014 proporcionando um grau de seletividade microbiana que distingue os AMPs de detergentes amplamente citot\u00f3xicos.<\/li>\n<li><strong>Neutraliza\u00e7\u00e3o de LPS e modula\u00e7\u00e3o da via TLR4<\/strong> \u2014 LL-37 binds directly to bacterial lipopolysaccharide (LPS) with high affinity, sequestering it from the TLR4 \/ MD-2 \/ CD14 receptor complex. This blocks LPS-driven NF-\u03baB activation, reduces downstream TNF-\u03b1 \/ IL-6 \/ IL-1\u03b2 release, and protects host tissue from sepsis-like cytokine storms during severe Gram-negative infections. The same property makes LL-37 a tool for dissecting LPS-driven signalling.<\/li>\n<li><strong>Imunomodula\u00e7\u00e3o via FPRL1 (receptor de pept\u00eddeo formil semelhante-1) e sinaliza\u00e7\u00e3o a jusante<\/strong> \u2014 A LL-37 age como um quimioatraente para neutr\u00f3filos, mon\u00f3citos e c\u00e9lulas T atrav\u00e9s da liga\u00e7\u00e3o ao FPRL1 (FPR2), um receptor acoplado \u00e0 prote\u00edna G expresso amplamente em c\u00e9lulas efetoras da imunidade inata. O mesmo receptor em c\u00e9lulas endoteliais media o efeito pr\u00f3-angiog\u00eanico da LL-37 \u2014 estimulando prolifera\u00e7\u00e3o, migra\u00e7\u00e3o e forma\u00e7\u00e3o de tubos em c\u00e9lulas endoteliais. A migra\u00e7\u00e3o de queratin\u00f3citos durante a reepiteliza\u00e7\u00e3o de feridas tamb\u00e9m \u00e9 dependente de FPRL1. O pept\u00eddeo tamb\u00e9m envolve receptores purin\u00e9rgicos P2X7 em macr\u00f3fagos, contribuindo para a modula\u00e7\u00e3o do inflamassoma.<\/li>\n<\/ul>\n<p>Uma caracter\u00edstica distintiva da biologia da LL-37 \u00e9 o <strong>\u201cequil\u00edbrio \u201despada vs escudo'<\/strong>: at low concentrations the peptide is dominantly immunomodulatory and tissue-protective, while at high local concentrations the direct membrane-disruptive activity dominates. This concentration-dependent functional switching is one reason why LL-37 has therapeutic-studies interest across both antimicrobial and wound-healing indications, and why detailed dose-response characterisation is critical in any in-vitro or in-vivo protocol. <\/p>\n<h2>Published Evidence<\/h2>\n<p>LL-37 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Antimicrobial-resistance studies<\/strong> \u2014 pain\u00e9is de concentra\u00e7\u00e3o inibit\u00f3ria m\u00ednima (CIM) de amplo espectro contra MRSA, Enterobact\u00e9rias produtoras de ESBL, cepas resistentes a carbapen\u00eamicos e pat\u00f3genos associados a biofilmes; benchmarking de pipeline de desenvolvimento de AMP<\/li>\n<li><strong>Biofilm studies<\/strong> \u2014 ensaios de preven\u00e7\u00e3o de biofilme, ensaios de disrup\u00e7\u00e3o de biofilme estabelecido contra <em>P. aeruginosa<\/em>, <em>S. aureus<\/em>, e <em>K. pneumoniae<\/em> \u2014 important in cystic-fibrosis and chronic-wound contexts<\/li>\n<li><strong>LPS \/ sepsis studies<\/strong> \u2014 ensaios de neutraliza\u00e7\u00e3o de LPS, dissec\u00e7\u00e3o de sinaliza\u00e7\u00e3o TLR4, modelos de tempestade de citocinas em choque s\u00e9ptico<\/li>\n<li><strong>Wound-healing and skin studies<\/strong> \u2014 keratinocyte migration assays, dermal-fibroblast and endothelial wound-closure models; one of the primary peptides in cutaneous wound-healing studies<\/li>\n<li><strong>Psoriasis pathogenesis studies<\/strong> \u2014 LL-37 \/ self-DNA \/ dissec\u00e7\u00e3o do eixo plasmocit\u00e1rio-dendr\u00edtico (LL-37 \u00e9 superexpresso na pele psori\u00e1sica e forma complexos com self-DNA para quebrar a toler\u00e2ncia via TLR9 em pDCs)<\/li>\n<li><strong>Atherosclerosis studies<\/strong> \u2014 LL-37 em macr\u00f3fagos da placa, intera\u00e7\u00e3o com LDL oxidado, modelos de inflama\u00e7\u00e3o vascular<\/li>\n<li><strong>Oncology<\/strong> \u2014 efeitos paradoxais pr\u00f3 e antitumorais dependendo do tipo de tumor (LL-37 \u00e9 pr\u00f3-proliferativo em alguns c\u00e2nceres via FPRL1, antitumoral em outros atrav\u00e9s da ruptura direta da membrana das c\u00e9lulas tumorais)<\/li>\n<li><strong>Innate-immunity mechanistic studies<\/strong> \u2014 sinaliza\u00e7\u00e3o FPRL1, modula\u00e7\u00e3o P2X7, biologia de armadilhas extracelulares de neutr\u00f3filos (NET), indu\u00e7\u00e3o de CAMP mediada por vitamina D<\/li>\n<\/ul>\n<p>For broader context on innate-immunity and host-defense peptide studies, see <a href=\"https:\/\/medsbase.com\/pt-br\/kpv-lysine-proline-valine\/\">KPV<\/a> (tripept\u00eddeo anti-inflamat\u00f3rio derivado de \u03b1-MSH), <a href=\"https:\/\/medsbase.com\/pt-br\/bpc-157\/\">BPC-157<\/a> (pentadecapept\u00eddeo de reparo tecidual de m\u00faltiplas vias), e <a href=\"https:\/\/medsbase.com\/pt-br\/tb-500\/\">TB-500<\/a> (fragmento de Thymosina Beta-4, amplo reparo tecidual). Navegue pelo <a href=\"https:\/\/medsbase.com\/pt-br\/peptides\/\">cat\u00e1logo de pept\u00eddeos<\/a> para compostos relacionados. <\/p>\n<h2>Concentra\u00e7\u00f5es e Dosagens Dispon\u00edveis<\/h2>\n<p>MedsBase stocks LL-37 in 5 mg lyophilized vials. Available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dosagem do Frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de Uso T\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos de Embalagem<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 multi-week MIC panels, biofilm assays, wound-healing experiments, LPS-neutralisation assays, immunomodulation dose-response work<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>LL-37 is supplied as the unmodified linear 37-mer free-acid form (no acylation, no PEGylation, no disulfide bridge). The peptide is sensitive to plastic adsorption \u2014 users should use low-binding tubes for stock storage and dilution. Working concentrations in published assays range from ~0.5 \u00b5g\/mL in chemotaxis assays up to ~50 \u00b5g\/mL in direct-killing antimicrobial assays. <\/p>\n<h2>Como Compara \u2014 LL-37 vs KPV<\/h2>\n<p>LL-37 e <a href=\"https:\/\/medsbase.com\/pt-br\/kpv-lysine-proline-valine\/\">KPV<\/a> are both used in innate-immunity studies but operate at completely different scales and target different machinery. LL-37 is a full 37-residue host-defense peptide combining direct antimicrobial membrane disruption with FPRL1-mediated immunomodulation. KPV (Lysine-Proline-Valine) is a 3-residue C-terminal fragment of \u03b1-melanocyte-stimulating hormone (\u03b1-MSH) that acts as a focused anti-inflammatory and modest antimicrobial peptide through melanocortin-receptor pathway modulation. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">LL-37<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">KPV<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Origem<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">C-terminal da catelicidina humana hCAP-18 (gene CAMP)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">C-terminal do horm\u00f4nio estimulante de melan\u00f3citos \u03b1 (\u03b1-MSH)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Comprimento<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">37 amino\u00e1cidos<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">3 amino\u00e1cidos<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Mecanismo prim\u00e1rio<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Interrup\u00e7\u00e3o da membrana anfip\u00e1tica \u03b1-h\u00e9lice + imunomodula\u00e7\u00e3o FPRL1<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sinaliza\u00e7\u00e3o anti-inflamat\u00f3ria modulada pela via da melanocortina (supress\u00e3o de NF-\u03baB)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Espectro antimicrobiano<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Amplo \u2014 Gram+, Gram\u2212, v\u00edrus envelopados, fungos, biofilmes<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Estreito \u2014 principalmente Gram+; mais fraco que LL-37 por ordens de magnitude<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Anti-inflamat\u00f3rio<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Forte (neutraliza\u00e7\u00e3o de LPS, modula\u00e7\u00e3o de citocinas)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Strong (canonical anti-inflammatory studies tripeptide)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Carga l\u00edquida<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">+6 (altamente cati\u00f4nico)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">+1<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Estrutura na membrana<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u03b1-h\u00e9lice anfip\u00e1tica<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sem estrutura secund\u00e1ria definida (motivo linear curto)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Indica\u00e7\u00e3o mais estudada<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Resist\u00eancia antimicrobiana, cicatriza\u00e7\u00e3o de feridas, psor\u00edase<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Modelos de DII\/colite, inflama\u00e7\u00e3o intestinal, dermatite at\u00f3pica<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on broad-spectrum antimicrobial activity, biofilm disruption, or membrane-pore mechanisms, LL-37 is the canonical reference peptide. For studies focused on melanocortin-pathway anti-inflammatory signalling at the cellular level, <a href=\"https:\/\/medsbase.com\/pt-br\/kpv-lysine-proline-valine\/\">KPV<\/a> \u00e9 a ferramenta mais seletiva. Veja tamb\u00e9m <a href=\"https:\/\/medsbase.com\/pt-br\/bpc-157\/\">BPC-157<\/a> for tissue-repair-focused anti-inflammatory studies and <a href=\"https:\/\/medsbase.com\/pt-br\/tb-500\/\">TB-500<\/a> para benchmarking amplo de reparo tecidual. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Precisa de \u00e1gua BAC?<\/strong> A reconstitui\u00e7\u00e3o de qualquer frasco liofilizado requer \u00e1gua bacteriost\u00e1tica est\u00e9ril. Combine este produto com nosso <a href=\"\/pt-br\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 frasco multidose de 30 mL, preservado com 0,9% de \u00e1lcool benz\u00edlico, grau USP.<\/div>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original para estoque de trabalho de curto prazo. Para armazenamento de longo prazo, congele frascos n\u00e3o abertos a \u221220 \u00b0C. O LL-37 liofilizado \u00e9 est\u00e1vel sob refrigera\u00e7\u00e3o por at\u00e9 24 meses e a \u221220 \u00b0C por at\u00e9 36 meses. Evite ciclos de congelamento-descongelamento do p\u00f3 liofilizado. Como todos os AMPs cati\u00f4nicos, o LL-37 tem tend\u00eancia a <strong>adsor\u00e7\u00e3o em pl\u00e1stico<\/strong> \u2014 mesmo pequenas perdas em tubos de polipropileno padr\u00e3o podem confundir dados de dose-resposta. Use tubos de baixa liga\u00e7\u00e3o (vidro siliconizado, Protein LoBind ou polipropileno pr\u00e9-revestido com albumina s\u00e9rica bovina) para armazenamento de estoque e dilui\u00e7\u00f5es seriais em tamp\u00f5es de ensaio com baixo teor de prote\u00edna. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> injete \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco (n\u00e3o diretamente sobre o liofilizado). Para um frasco de 5 mg, 1,0 mL de \u00e1gua bacteriost\u00e1tica produz uma concentra\u00e7\u00e3o de trabalho de 5 mg\/mL; 2,0 mL produzem um estoque de trabalho de 2,5 mg\/mL. Agite suavemente \u2014 n\u00e3o agite vigorosamente, pois a forma\u00e7\u00e3o de espuma aprisiona ar e pode perturbar o dobramento da h\u00e9lice. Deixe o p\u00f3 dissolver completamente (geralmente 1\u20132 minutos) antes de retirar. Para aplica\u00e7\u00f5es sens\u00edveis a agentes bacteriost\u00e1ticos (experimentos de cultura de c\u00e9lulas), reconstitua em \u00e1gua est\u00e9ril ou \u00e1cido ac\u00e9tico 0,01%. Uma vez reconstitu\u00eddo, armazene o frasco a 2\u20138 \u00b0C e use dentro de 14\u201328 dias. Proteja da luz. Descarte se aparecer turva\u00e7\u00e3o, part\u00edculas ou mudan\u00e7a de cor. <\/p>\n<h2>Perguntas Frequentes<\/h2>\n<h3>LL-37 \u00e9 o mesmo que catelicidina?<\/h3>\n<p>LL-37 \u00e9 o pept\u00eddeo ativo de 37 amino\u00e1cidos C-terminal liberado da catelicidina humana (a pr\u00f3-forma inativa hCAP-18, codificada pelo gene CAMP). Catelicidina \u00e9 o nome da fam\u00edlia e se refere a muitas esp\u00e9cies de vertebrados; LL-37 \u00e9 o nome espec\u00edfico do pept\u00eddeo ativo da catelicidina humana. Outros nomes que voc\u00ea pode encontrar na literatura \u2014 CAP-18 e FALL-39 \u2014 referem-se \u00e0 mesma mol\u00e9cula de diferentes conven\u00e7\u00f5es hist\u00f3ricas de nomenclatura. <\/p>\n<h3>Como LL-37 \u00e9 diferente das defensinas?<\/h3>\n<p>LL-37 e as defensinas (\u03b1- e \u03b2-defensinas) s\u00e3o as duas principais fam\u00edlias de pept\u00eddeos antimicrobianos de mam\u00edferos. As defensinas s\u00e3o menores, ricas em ciste\u00edna e adotam estruturas de folha \u03b2 estabilizadas por 3 liga\u00e7\u00f5es dissulfeto. LL-37 \u00e9 um pept\u00eddeo cati\u00f4nico linear mais longo que adota uma h\u00e9lice \u03b1 anfip\u00e1tica em ambientes de membrana \u2014 sem ponte dissulfeto. Ambas as classes compartilham ampla atividade antimicrobiana e pap\u00e9is imunomoduladores, mas operam por mecanismos estruturalmente distintos. <\/p>\n<h3>Qual \u00e9 a concentra\u00e7\u00e3o efetiva t\u00edpica de LL-37 em ensaios antimicrobianos?<\/h3>\n<p>As concentra\u00e7\u00f5es inibit\u00f3rias m\u00ednimas (CIMs) publicadas para LL-37 contra pat\u00f3genos Gram-positivos e Gram-negativos suscet\u00edveis geralmente variam de 1 a 32 \u00b5g\/mL, dependendo da cepa, for\u00e7a i\u00f4nica do tamp\u00e3o de ensaio e formato de biofilme vs planct\u00f4nico. Concentra\u00e7\u00f5es mais altas (50\u2013100 \u00b5g\/mL) s\u00e3o comumente usadas para estudos de disrup\u00e7\u00e3o direta de membrana e ensaios de erradica\u00e7\u00e3o de biofilme. Leituras imunomodulat\u00f3rias (quimiotaxia, neutraliza\u00e7\u00e3o de LPS, migra\u00e7\u00e3o de queratin\u00f3citos) geralmente usam concentra\u00e7\u00f5es muito mais baixas (0,5\u201310 \u00b5g\/mL). Determine as faixas de dose a partir da literatura revisada por pares apropriada ao seu protocolo espec\u00edfico. <\/p>\n<h3>Por que a adsor\u00e7\u00e3o em pl\u00e1stico \u00e9 importante para LL-37?<\/h3>\n<p>AMPs cati\u00f4nicos como LL-37 podem adsorver significativamente \u00e0s superf\u00edcies de pl\u00e1sticos de laborat\u00f3rio padr\u00e3o, como polipropileno e poliestireno, especialmente em tamp\u00f5es com baixo teor de prote\u00edna. Perdas de 30\u201380% em uma \u00fanica transfer\u00eancia de tubo foram documentadas na literatura para pept\u00eddeos cati\u00f4nicos em baixas concentra\u00e7\u00f5es. Isso pode produzir subestima\u00e7\u00e3o sistem\u00e1tica da atividade, particularmente em s\u00e9ries de dilui\u00e7\u00e3o para determina\u00e7\u00e3o de CIM. Use tubos de baixa liga\u00e7\u00e3o, pr\u00e9-revesta os tubos com BSA ou inclua prote\u00edna carreadora em tamp\u00f5es de dilui\u00e7\u00e3o, conforme apropriado para a leitura do ensaio. <\/p>\n<h3>Como LL-37 distingue membranas microbianas de membranas de mam\u00edferos?<\/h3>\n<p>A seletividade surge da composi\u00e7\u00e3o da membrana. As membranas microbianas (especialmente as membranas externas Gram-negativas e as membranas citoplasm\u00e1ticas Gram-positivas) s\u00e3o ricas em lip\u00eddios carregados negativamente (fosfatidilglicerol, cardiolipina, LPS, \u00e1cido lipoteicoico). As membranas citoplasm\u00e1ticas de mam\u00edferos possuem uma folha externa zwitteri\u00f4nica (fosfatidilcolina, esfingomielina) e um alto teor de colesterol que estabiliza a bicamada. A face cati\u00f4nica de LL-37 engaja preferencialmente a superf\u00edcie microbiana carregada negativamente; a membrana de mam\u00edferos estabilizada pelo colesterol \u00e9 muito menos suscet\u00edvel \u00e0 inser\u00e7\u00e3o. A seletividade \u00e9 dependente da concentra\u00e7\u00e3o \u2014 em concentra\u00e7\u00f5es locais muito altas, LL-37 tamb\u00e9m pode se tornar citot\u00f3xico para c\u00e9lulas de mam\u00edferos. <\/p>\n<h3>O que \u00e9 o modelo \u201cespada vs escudo\u201d da fun\u00e7\u00e3o de LL-37?<\/h3>\n<p>The model describes the concentration-dependent functional switching of LL-37: at low concentrations (&lt;5 \u00b5g\/mL) the peptide is dominantly immunomodulatory and tissue-protective \u2014 chemotactic, pro-angiogenic, LPS-neutralising. At high concentrations (&gt;20 \u00b5g\/mL) the direct membrane-disruptive antimicrobial activity dominates. This dual nature underlies LL-37&#8217;s diverse roles in host defense and is one of the reasons careful dose-response characterisation is essential in any in-vitro or in-vivo context. <\/p>\n<h3>Qual \u00e9 a liga\u00e7\u00e3o entre LL-37 e psor\u00edase?<\/h3>\n<p>LL-37 is markedly overexpressed in psoriatic skin lesions and binds avidly to self-DNA and self-RNA released from damaged keratinocytes. These LL-37 \/ self-nucleic-acid complexes activate plasmacytoid dendritic cells via TLR9 (DNA) and TLR7 (RNA), driving the IFN-\u03b1-rich autoimmune-like inflammation that characterises psoriasis. Targeting the LL-37 \/ pDC \/ TLR axis is an active area of psoriasis pharmacology studies. <\/p>\n<h3>Por que alguns estudos sobre c\u00e2ncer s\u00e3o pr\u00f3-tumor enquanto outros s\u00e3o anti-tumor?<\/h3>\n<p>LL-37 tem efeitos documentados dependentes do contexto no c\u00e2ncer. Em alguns tipos de tumor (ov\u00e1rio, mama, pulm\u00e3o, colorretal), a express\u00e3o elevada de LL-37 correlaciona-se com pior progn\u00f3stico \u2014 provavelmente por meio de sinaliza\u00e7\u00e3o pr\u00f3-proliferativa e pr\u00f3-angiog\u00eanica mediada por FPRL1. Em outros (g\u00e1strico, melanoma em alguns modelos), LL-37 tem efeito citot\u00f3xico direto de desestabiliza\u00e7\u00e3o de membrana em c\u00e9lulas tumorais, com atividade anti-tumor mais fraca. O efeito l\u00edquido depende do tipo de tumor, concentra\u00e7\u00e3o local, express\u00e3o de FPRL1 e composi\u00e7\u00e3o do microambiente tumoral. <!-- medsbase-related-alts-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 \u00danico pept\u00eddeo antimicrobiano catelicidina humano (37 aa)<br \/>\n\u2705 \u03b1-h\u00e9lice anfip\u00e1tica; carga l\u00edquida +6<br \/>\n\u2705 Amplo espectro: Gram+, Gram\u2212, v\u00edrus envelopados, biofilmes<br \/>\n\u2705 Imunomodulador via FPRL1 + neutraliza\u00e7\u00e3o de LPS<br \/>\n\u2705 Estudo em resist\u00eancia antimicrobiana, cicatriza\u00e7\u00e3o de feridas, psor\u00edase, oncologia<\/p>\n<p><strong>LL-37<\/strong> cont\u00e9m composto de pept\u00eddeo sint\u00e9tico.<\/p>","protected":false},"featured_media":71408,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6465,6464,6463,5441],"class_list":["post-71392","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-cap-18","product_tag-cathelicidin","product_tag-ll-37","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product\/71392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/comments?post=71392"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media\/71408"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media?parent=71392"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_brand?post=71392"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_cat?post=71392"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_tag?post=71392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}